A recent study highlights the financial viability of screening for liver fibrosis in individuals suspected of having metabolic dysfunction-associated steatotic liver disease (MASLD). Utilizing noninvasive serological tests, the research underscores significant benefits in early detection and management.
Key Study Outcomes
The investigation employed decision tree and Markov models to evaluate life-years, quality-adjusted life-years (QALYs), costs, and the incremental cost-effectiveness ratio (ICER) for screening versus no screening within the United States healthcare system. Results revealed that the prevalence of advanced hepatic fibrosis was markedly higher in suspected MASLD cases when identified using the fatty liver index (FLI) and hepatic steatosis index (HSI) compared to those without MASLD.
Healthcare Implications
Screening strategies based on FLI and HSI demonstrated ICERs of $78,647 and $84,874 per QALY, respectively, both falling below the $100,000/QALY threshold deemed cost-effective in the U.S. Notably, screening was not cost-effective for subgroups lacking MASLD indications. Similar positive outcomes were observed when applying data from Korea, suggesting a broader applicability of the findings.
- Early detection through FLI and HSI can lead to timely interventions, potentially reducing long-term healthcare costs.
- Implementing a two-step screening process in primary care can enhance the efficiency of MASLD management.
- Cost-effectiveness varies significantly across different patient subgroups, emphasizing the need for targeted screening approaches.
The study advocates for the integration of FLI and HSI-based screening algorithms in primary care settings, offering a strategic approach to managing advanced hepatic fibrosis in MASLD-suspected patients. These findings provide valuable insights for healthcare policymakers and practitioners aiming to optimize resource allocation and improve patient outcomes in liver disease management.
By adopting these cost-effective screening methods, healthcare systems can better identify and treat individuals at risk of severe liver complications, ultimately enhancing the quality of life for patients while maintaining economic sustainability. The research sets a foundation for future studies to explore and refine screening protocols, ensuring that liver fibrosis detection remains both clinically effective and financially feasible.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
